ERBB2 and ductal breast carcinoma in situ: It has been demonstrated that in ductal carcinoma in situ, the human epidermal growth factor receptor 2 (HER2)-positive/progesterone (PR)-negative/ER-negative cancers showed a higher recurrence risk than HER2-negative/PR-positive/ER-positive cancers.